Home
  >  
Section 42
  >  
Chapter 41,613

The dopamine D2 agonists RU 24213 and RU 24926 are also kappa-opioid receptor antagonists

Fortin, M.; Degryse, M.; Petit, F.; Hunt, P.F.

Neuropharmacology 30(4): 409-412

1991

ISSN/ISBN: 0028-3908
PMID: 1677169
DOI: 10.1016/0028-3908(91)90068-m
Accession: 041612598
Download citation:  
Text
  |  
BibTeX
  |  
RIS
The di-(phenethyl)-amine derivatives, RU 24213 and RU 24926 are widely used as selective dopamine D2-receptor agonists. Binding studies now show that they also have affinity for the kappa-opioid receptor. Their affinity is not greatly reduced in the presence of NaCl/GTP, suggesting an antagonist action. This is confirmed for RU 24926, the more active of the two, using the field-stimulated rabbit vas-deferens. With respect to the mu-receptor, RU 24926 shows low binding affinity and also an antagonist effect. These results demonstrate kappa- as well as mu-antagonist activity in a novel chemical series. Moreover, since the kappa-receptor may regulate dopamine release, the results of experiments using these compounds as dopamine D2 agonists should be interpreted with caution.

PDF emailed within 0-6 h: $19.90




Related References

Ito, S.; Mori, T.; Sawaguchi, T. 2006: Differential effects of micro-opioid, delta-opioid and kappa-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice Behavioural Pharmacology 17(8): 691-701
Wood, P.L. 1983: Opioid receptor affinities of kappa agonists, agonist/antagonists and antagonists in vitro and in vivo Progress in Neuro-Psychopharmacology and Biological Psychiatry 7(4-6): 657-662
Iwamoto, E.T. 1981: Locomotor activity and antinociception after putative mu, kappa and sigma opioid receptor agonists in the rat: influence of dopaminergic agonists and antagonists Journal of Pharmacology and Experimental Therapeutics 217(2): 451-460
Neumeyer, J.L.; Bidlack, J.M.; Zong, R.; Bakthavachalam, V.; Gao, P.; Cohen, D.J.; Negus, S.S.; Mello, N.K. 2000: Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence Journal of Medicinal Chemistry 43(1): 114-122
Mulder, A.H.; Wardeh, G.; Hogenboom, F.; Frankhuyzen, A.L. 1984: Kappa opioid and delta opioid receptor agonists differentially inhibit striatal dopamine and acetyl choline release Nature (London) 308(5956): 278-280
Neumeyer, J.L.; Gu, X.H.; van Vliet, L.A.; DeNunzio, N.J.; Rusovici, D.E.; Cohen, D.J.; Negus, S.S.; Mello, N.K.; Bidlack, J.M. 2001: Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan Bioorganic and Medicinal Chemistry Letters 11(20): 2735-2740
Kong, H.; Raynor, K.; Yano, H.; Takeda, J.; Bell, G.I.; Reisine, T. 1994: Agonists and antagonists bind to different domains of the cloned kappa opioid receptor Proceedings of the National Academy of Sciences of the United States of America 91(17): 8042-8046
Li, F.C.; Jen, M.F.; Wan, X.S.T. 1994: Synergistic analgesia of intrathecal co-administration of kappa opioid receptor agonists and NMDA receptor antagonists in rats FASEB Journal 8(4-5): A629
Li, F.C.; Sun, X.J.; Hu, W.H.; Jen, M.F. 1994: Intrathecal co-administration of kappa opioid receptor agonists and NMDA receptor antagonists induces synergistic analgesia in rats Yao Xue Xue Bao 29(12): 881-886
Mori, T.; Nomura, M.; Yoshizawa, K.; Nagase, H.; Sawaguchi, T.; Narita, M.; Suzuki, T. 2006: Generalization of NMDA-receptor antagonists to the discriminative stimulus effects of kappa-opioid receptor agonists U-50,488H, but not TRK-820 in rats Journal of Pharmacological Sciences 100(2): 157-161
Marin, C.; Engber, T.M.; Chaudhuri, P.; Peppe, A.; Chase, T.N. 1991: Effects of kappa opioid agonists on dopamine receptor mediated behaviors Society for Neuroscience Abstracts 17(1-2): 97
Elwan, M.A.; Ghazal, A.M.; Sharabi, F.M.; Soliman, N.R.I. 1996: Alterations of mu- and kappa-opioid receptor binding in specific rat regions following repeated of selective dopamine receptor agonists FASEB Journal 10(3): A163
Butelman, E.R.; Kreek, M.J. 2001: Kappa-Opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D(2)-like receptor agonists European Journal of Pharmacology 423(2-3): 243-249
Yilmaz, B.; Gilmore, D.P. 1999: Effects of mu, kappa, and delta opioid receptor agonists and antagonists on rat hypothalamic noradrenergic neurotransmission Brain Research Bulletin 48(5): 491-495
Buckingham, J.C.; Cooper, T.A. 1986: The effects of mu delta and kappa opioid receptor agonists and antagonists on corticotropin releasing factor secretion British Journal of Pharmacology 87(Suppl): 60P
Collins, S.L.; D'Addario, C.; Izenwasser, S. 2001: Effects of kappa-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission European Journal of Pharmacology 426(1-2): 25-34
Schlösser, B.; Kudernatsch, M.B.; Sutor, B.; ten Bruggencate, G. 1995: Delta, mu and kappa opioid receptor agonists inhibit dopamine overflow in rat neostriatal slices Neuroscience Letters 191(1-2): 126-130
Engber, T.M.; Boldry, R.C.; Chase, T.N. 1991: The kappa-opioid receptor agonist spiradoline differentially alters the rotational response to dopamine D1 and D2 agonists European Journal of Pharmacology 200(1): 171-173
Mulder, A.H.; Wardeh, G.; Hogenboom, F.; Frankhuyzen, A.L. 1984: Kappa- and delta-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release Nature 308(5956): 278-280
Spangler, R.; Zhou, Y.; Unterwald, E.; Yuferov, V.; Ho, A.; Kreek, M.J. 1994: Kappa opioid receptor mRNA levels in the rat brain Effects of dopamine antagonists and cocaine Regulatory Peptides 54(1): 283